A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine
Launched by HOFFMANN-LA ROCHE · May 2, 2007
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 1 diabetic patients, 18-60 years of age
- • Diabetic for \>2 years
- • Treated with CSII for \>=6 months
- • HbA1c \<8.5%
- Exclusion Criteria:
- • Treatment with daily insulin injections
- • Inability to handle pump therapy
- • Untreated retinopathy
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bergamo, , Italy
Padova, , Italy
Pisa, Toscana, Italy
Brescia, Lombardia, Italy
Patients applied
Trial Officials
Andreas Buhr
Study Director
Disetronic Medical Systems AG
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials